In vitro immune modulation by antibodies coupled to tumour cells

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Autologous tumor cell modification for cancer immunotherapy often relies on genetic engineering.
• Current gene transfer methods face limitations in efficiency and applicability to diverse tumor types.
• There is a need for rapid, efficient, and non-genetic approaches for tumor cell modification.

Purpose of the Study:

• To develop a highly efficient in vitro procedure for modifying tumor cells to express immune-modulatory proteins.
• To demonstrate the feasibility of a non-genetic immunotherapy protocol using surface protein labeling.
• To enable co-stimulation of T cells using modified autologous tumor cells.

Main Methods:

• Utilized succinimide esters for covalent biotinylation of cell surface proteins.
• Employed an avidin bridge to immobilize protein G'-biotin, anchoring immunoglobulin (Ig) molecules.
• Demonstrated T cell co-stimulation in vitro using anti-human CD28 monoclonal antibody bound to modified tumor cells.

Main Results:

• Achieved modification of over 99% of tumor cells in vitro.
• Procedure completed within 24 hours, scalable to any cell number.
• Modified cells successfully co-stimulated T cells, indicating functional immune engagement.

Conclusions:

• The developed method offers a rapid, highly efficient, and non-genetic approach for tumor cell modification.
• This technique represents a significant step towards a practical, 'off-the-shelf' immunotherapy.
• The simplicity and use of common reagents make this method broadly applicable for cancer immunotherapy development.